Bipolar Clinical Trial
Official title:
Seeking Genetic Counseling: What Motivates Families At Risk For Psychiatric Illness?
Verified date | February 6, 2008 |
Source | National Institutes of Health Clinical Center (CC) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This study will examine those who will seek and those who are most likely to benefit from
genetic counseling for psychiatric disorders. It will identify themes related to perceived
risks, benefits, and possible motivations for seeking genetic counseling among families
affected by bipolar disorder. It will then use those themes to generate a starting point for
a framework to guide further research and to improve genetics services as they are currently
practiced.
Adults with bipolar disorder and the adult siblings of people with bipolar disorder are
eligible for this study. In a 60- to 90-minute telephone interview, participants are asked
questions related to their thoughts about the causes of bipolar disorder, their experiences
with the illness, their concerns about the disorder occurring again in their families, and
their feelings about the value of discussing these issues with health care professionals.
They also are asked questions about the mental health of their close family members and their
own mental health.
Status | Completed |
Enrollment | 50 |
Est. completion date | February 6, 2008 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
- INCLUSION CRITERIA: Individuals over 18 years of age who have been diagnosed with bipolar disorder (per their own report; no screening will be performed), and/or the adult siblings of affected individuals. Participants do not have to be sibling pairs, i.e., an affected individual may be included without the participation of their unaffected sibling, and visa versa. Participants must be able to speak English fluently. EXCLUSION CRITERIA: Those under 18 years of age will not be included. First-degree relatives other than full siblings will not be included. If a participant is symptomatic to the point that the interview is compromised, as determined by the PI who has considerable experience counseling affected individuals, the PI will end the interview and any data collected will be destroyed. If possible, the interview will be rescheduled. We will encourage symptomatic individuals to seek care from their mental health provider, or we will make a referral if the individual does not have a provider. |
Country | Name | City | State |
---|---|---|---|
United States | National Human Genome Research Institute (NHGRI), 9000 Rockville Pike | Bethesda | Maryland |
Lead Sponsor | Collaborator |
---|---|
National Human Genome Research Institute (NHGRI) |
United States,
Hodgkinson KA, Murphy J, O'Neill S, Brzustowicz L, Bassett AS. Genetic counselling for schizophrenia in the era of molecular genetics. Can J Psychiatry. 2001 Mar;46(2):123-30. Review. — View Citation
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT02133170 -
"Mindfulness vs Psychoeducation in Bipolar Disorder"
|
N/A | |
Completed |
NCT02189057 -
A Pharmacokinetic/Pharmacodynamic Genetic Variation Treatment Algorithm Versus Treatment As Usual for Management Of Depression
|
N/A | |
Completed |
NCT00666432 -
Bipolar and Schizophrenia Consortium for Parsing Intermediate Phenotypes
|
||
Completed |
NCT02184767 -
Study to Assess the Safety and Pharmacokinetics of ADASUVE® at Doses of 2.5, 5, or 10 mg in Children and Adolescents (10 Through 17 Years of Age) With Any Condition Warranting Chronic Use of an Antipsychotic Medication
|
Phase 1 | |
Terminated |
NCT01131559 -
Adjunctive Lisdexamfetamine (LDX) in Bipolar Depression
|
Phase 3 | |
Recruiting |
NCT01047215 -
Heart Rate Changes in Schizophrenic and Bipolar Patients Under the Medication of Aripiprazole and Quetiapine
|
Phase 4 | |
Enrolling by invitation |
NCT00969930 -
Genetic Association Study Between Single Nucleotide Polymorphisms (SNPs) and Cognitive Performance in Young Bipolar Type I Patients: LICAVALGENE
|
N/A |